Covid-19: FDC launches first Favipiravir Oral Suspension Favenza in India

Published On 2021-07-13 07:05 GMT   |   Update On 2021-07-13 12:24 GMT
Advertisement

Mumbai: Home-grown pharma major, FDC Limited, has announced the launch of India's first oral suspension of Favipiravir - Favenza Oral Suspension, used to treat mild to moderate cases of COVID-19.

This prescription-only solution is currently available at all retail medical outlets and hospital pharmacies across the country.

The Favenza suspension is unique due to its Convenient Loading Dose (Day 1) of 18 ml in the morning and 18 ml in the evening. The results of which are equivalent to 9 tablets of Favipiravir 400mg making the process of Covid-19 treatment hassle free.

Advertisement

Mr. Mayank Tikkha, General Manager – Business Development & Commercial Excellence, FDC Ltd. commented, "With positive cases on the rise again, now is the time to provide healthcare warriors in our country with viable options in this continuous battle against this disease. In order to combat Covid-19, we believe in offering best efficacy along with convenience to our patients and as such we have focused our efforts in making the process of Covid-19 treatment hassle-free."

India, with the second highest number of cases globally, is seeing about 50,000 cases being added every day. Though on a decline, the second wave is far from over and there are fears of an oncoming third wave.

Read also: Glenmark PMS Study interim data supports favipiravir safety, effectiveness

FDC Limited is a fully integrated research-oriented pharmaceutical company engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). FDC's formulation department designs and develops products for various global markets and the highly regulated markets of US and Europe. FDC markets more than 300 products in India and exports many of these to over 50 countries. Some of its brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.




Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News